Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Breast Neoplasms 84Colorectal Neoplasms 42Rectal Neoplasms 40Carcinoma, Non-Small-Cell Lung 27Esophageal Neoplasms 24Esophageal Squamous Cell Carcinoma 23Stomach Neoplasms 19Lung Neoplasms 19Squamous Cell Carcinoma of Head and Neck 17Colonic Neoplasms 17Pancreatic Neoplasms 15Adenocarcinoma Of Esophagus 15Sarcoma 14Prostatic Neoplasms 13Neoplasm Metastasis 13Neoplasms 12Head and Neck Neoplasms 12Ovarian Neoplasms 11Carcinoma, Hepatocellular 11Inflammatory Breast Neoplasms 9Uterine Cervical Neoplasms 8Urinary Bladder Neoplasms 8Osteosarcoma 8Fallopian Tube Neoplasms 8Central Nervous System Neoplasms 8Carcinoma, Intraductal, Noninfiltrating 8Kidney Neoplasms 7Multiple Myeloma 6Glioblastoma 6Carcinoma, Renal Cell 6

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236aldesleukin 134Cyclophosphamide 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 67dabrafenib 65fludarabine phosphate 61sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35cobimetinib 32Magnetic Resonance Spectroscopy 32Introns 30Specimen Handling 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Melanoma × Neoadjuvant Therapy × Clear all
NCT06587451 2026-02-24

Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®

Sandoz

Phase 3 Terminated
52 enrolled
Dermatologic

Melanoma

NCT00324727 2021-06-21

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

Delcath Systems Inc.

Phase 3 Completed
93 enrolled
Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT00667901 2009-12-11

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

Rutgers, The State University of New Jersey

Phase 1 Terminated
15 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡